Search

Your search keyword '"Vucinic, V."' showing total 198 results
Start Over Author "Vucinic, V."
198 results on '"Vucinic, V."'

1. Improving post-cellular therapy care with an interdisciplinary, cross-regional, cross-sectoral, digital-aided approach

Author

Schneider, M, Egger-Heidrich, K, Müller, G, Schmädig, R, Schmidt, F, Leppla, L, Geest, SD, Teynor, A, Wolfien, M, Sedlmayr, M, Hänel, M, Vucinic, V, Schmitt, J, Platzbecker, U, Schetelig, J, Bornhäuser, M, Middeke, JM, Schneider, M, Egger-Heidrich, K, Müller, G, Schmädig, R, Schmidt, F, Leppla, L, Geest, SD, Teynor, A, Wolfien, M, Sedlmayr, M, Hänel, M, Vucinic, V, Schmitt, J, Platzbecker, U, Schetelig, J, Bornhäuser, M, and Middeke, JM

Published
2024

2. Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.

Author

Schubert, M., primary, Ayuk, F. A., additional, Bethge, W., additional, von Bonin, M., additional, Vucinic, V., additional, Wagner‐Drouet, E. M., additional, Subklewe, M., additional, Baldus, C. D., additional, Glass, B., additional, Marks, R., additional, Mougiakakos, D., additional, Schroers, R., additional, Stelljes, M., additional, Topp, M. S., additional, Wulf, G., additional, Kröger, N., additional, and Dreger, P., additional

Published
2023
Full Text
View/download PDF

3. Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cells

Author

Weiss, R., primary, Fernandez, C. P., additional, Boldt, A., additional, Hoffmann, S., additional, Krauss, S., additional, Bach, E., additional, Kirchberg, J., additional, Kurch, L., additional, Merz, M., additional, Metzeler, K., additional, Herling, C., additional, Jentzsch, M., additional, Schwind, S., additional, Petermann, N., additional, Franz, P., additional, Herling, M., additional, Denecke, T., additional, Sabri, O., additional, Fricke, S., additional, Kluge, R., additional, Sack, U., additional, Franke, G., additional, Koehl, U., additional, Platzbecker, U., additional, Georgi, T., additional, and Vucinic, V., additional

Published
2023
Full Text
View/download PDF

4. Immunotherapy: IN-DEPTH CHARACTERIZATION OF THE IMMUNE MICROENVIRONMENT OF PATIENTS UNDERGOING CAR T CELL THERAPY

Author

Weirauch, U., primary, Alb, M., additional, Weiß, R., additional, Löffler, D., additional, Kopfnagel, V., additional, Blumert, C., additional, Düll, J., additional, Scheller, L., additional, Boldt, A., additional, Vucinic, V., additional, Platzbecker, U., additional, Köhl, U., additional, Hudecek, M., additional, and Reiche, K., additional

Published
2023
Full Text
View/download PDF

6. Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations

Author

Niederwieser, C., Starke, S., Fischer, L., Krahl, R., Beck, J., Gruhn, B., Ebell, W., Körholz, D., Wößmann, W., Bader, P., Lang, P., Al-Ali, H-K., Cross, M., Eisfeld, A-K., Heyn, S., Vucinic, V., Franke, G-N., Lange, T., Pönisch, W., Behre, G., and Christiansen, H.

Published
2016
Full Text
View/download PDF

7. P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION

Author

Bischof, L., primary, Ussmann, J., additional, Brauer, D., additional, Backhaus, D., additional, Herrmann, L., additional, Franke, G.-N., additional, Vucinic, V., additional, Metzeler, K. H., additional, Platzbecker, U., additional, Schwind, S., additional, and Jentzsch, M., additional

Published
2022
Full Text
View/download PDF

8. P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY

Author

Derigs, P., primary, Bethge, W., additional, Holtick, U., additional, von Tresckow, B., additional, Ayuk, F., additional, Penack, O., additional, Vucinic, V., additional, von Bonin, M., additional, Baldus, C., additional, Mougiakakos, D., additional, Wulf, G., additional, Schnetzke, U., additional, Stelljes, M., additional, Thomas, S., additional, Schroers, R., additional, Kroeger, N., additional, and Dreger, P., additional

Published
2022
Full Text
View/download PDF

9. P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS

Author

Ussmann, J., primary, Hell, S., additional, Schetschorke, B., additional, Friedrich, G., additional, Pfrepper, C., additional, Schwind, S., additional, Jentzsch, M., additional, Vucinic, V., additional, Herling, M., additional, Platzbecker, U., additional, and Franke, G.-N., additional

Published
2022
Full Text
View/download PDF

10. P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY

Author

Herrera, A. F., primary, Lavie, D., additional, Johnson, N. A., additional, Avigdor, A., additional, Borchmann, P., additional, Andreadis, C., additional, Bazargan, A., additional, Gregory, G., additional, Keane, C., additional, Inna, T., additional, Vucinic, V., additional, Zinzani, P. L., additional, Zhang, H., additional, Pillai, P., additional, Marinello, P., additional, and Timmerman, J., additional

Published
2022
Full Text
View/download PDF

11. P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY

Author

Gregory, G., primary, Timmerman, J., additional, Lavie, D., additional, Borchmann, P., additional, Herrera, A. F., additional, Minuk, L., additional, Vucinic, V., additional, Armand, P., additional, Avigdor, A., additional, Gasiorowski, R., additional, Herishanu, Y., additional, Keane, C., additional, Kuruvilla, J., additional, Palcza, J., additional, Pillai, P., additional, Marinello, P., additional, and Johnson, N. A., additional

Published
2022
Full Text
View/download PDF

12. S287: FACTORS INFLUENCING AUTOLOGOUS LYMPHOCYTE COLLECTIONS FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS – THE ROLE OF T-CELL SENESCENCE

Author

Vucinic, V., primary, Tumewu, T., additional, Brückner, M., additional, Jentzsch, M., additional, Ramdohr, F., additional, Buhmann, R., additional, Remane, Y., additional, Hoffmann, S., additional, Janz, M., additional, Penack, O., additional, Vogtmann, G., additional, Ruschpler, E., additional, Bullinger, L., additional, Keller, U., additional, Cross, M., additional, Schwind, S., additional, Herling, M., additional, Franke, G.-N., additional, Bach, E., additional, Reinhard, H., additional, and Platzbecker, U., additional

Published
2022
Full Text
View/download PDF

15. Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.

Author

Timmerman J., Lavie D., Johnson N.A., Avigdor A., Borchmann P., Andreadis C., Bazargan A., Gregory G., Keane C., Inna T., Vucinic V., Luigi Zinzani P., Zhang H., Pillai P., Marinello P., Herrera A.F., Timmerman J., Lavie D., Johnson N.A., Avigdor A., Borchmann P., Andreadis C., Bazargan A., Gregory G., Keane C., Inna T., Vucinic V., Luigi Zinzani P., Zhang H., Pillai P., Marinello P., and Herrera A.F.

Abstract

Background: PD-1 inhibitors are a standard of care for R/R cHL but optimal therapy after anti-PD-1 therapy failure is yet to be defined. LAG-3/PD-1 coblockade has demonstrated antitumor activity in preclinical models. This multicohort phase 1/2 study (NCT03598608) evaluated the safety and efficacy of favezelimab (MK-4280), a humanized IgG4 LAG-3 inhibitor, plus the PD-1 inhibitor pembrolizumab (pembro) in pts with R/R hematologic malignancies. Cohort 2 focused on pts with R/R cHL refractory to anti-PD-1 therapy. Method(s): This study included a safety lead-in phase (part 1) to determine recommended phase 2 dose (RP2D) followed by a dose-expansion phase (part 2). Eligible pts in cohort 2 had R/R cHL, relapsed after or were ineligible for autologous stem cell transplantation (ASCT), and progressed after >=2 doses of anti-PD-1 therapy (within 12 weeks of last dose). In part 1, pts from all cohorts received pembro IV 200 mg Q3W and favezelimab IV 200 mg or 800 mg Q3W. Dose-finding based on occurrence of dose-limiting toxicities (DLT) was determined using an mTPI design. In part 2, pts received pembro + favezelimab at the established RP2D for up to 35 cycles. Primary end point was safety. Secondary end point was ORR. DOR, PFS, and OS were exploratory. Result(s): Only 1 DLT (autoimmune hepatitis [grade 4]) was observed among the first 6 pts from all cohorts in part 1 at the favezelimab 200 mg dose; thus, the dose was escalated to 800 mg. No DLTs were observed in 15 additional pts at the 800 mg dose. Favezelimab RP2D was defined as 800 mg Q3W + pembro 200 mg Q3W. In cohort 2, 33 pts were enrolled; median age was 37 yrs, 64% had ECOG PS 0, and 94% had >=4 prior lines of therapy. After a median follow-up of 16.5 mo, ORR for pts receiving favezelimab 800 mg (n = 29) was 31% (95% CI, 15-51; CR, 2 [7%]; PR, 7 [24%]); 66% of responders had an anti-PD-1-based regimen as most recent line of therapy at study entry. 23 of 29 pts (79%) had reduction from baseline in target lesions. M

Published
2022

16. Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

Author

Johnson N.A., Lavie D., Borchmann P., Gregory G., Herrera A.F., Minuk L., Vucinic V., Armand P., Avigdor A., Gasiorowski R., Herishanu Y., Keane C., Kuruvilla J., Palcza J., Pillai P., Marinello P., Timmerman J., Johnson N.A., Lavie D., Borchmann P., Gregory G., Herrera A.F., Minuk L., Vucinic V., Armand P., Avigdor A., Gasiorowski R., Herishanu Y., Keane C., Kuruvilla J., Palcza J., Pillai P., Marinello P., and Timmerman J.

Abstract

Background: PD-1 inhibitors are a standard of care in pts with R/R cHL but new approaches are still needed to deepen and lengthen responses. Dual blockade of PD-1 and LAG-3 has demonstrated antitumor activity in preclinical models. The multicohort phase 1/2 MK-4280-003 study (NCT03598608) evaluated the safety and efficacy of favezelimab (MK-4280), a humanized IgG4 LAG-3 inhibitor, plus pembrolizumab (pembro; a PD-1 inhibitor) in pts with R/R hematologic malignancies. This analysis focused on anti-PD-1-naive pts with R/R cHL (cohort 1). Method(s): This study included a safety lead-in phase (part 1) to determine the recommended phase 2 dose (RP2D) followed by a dose-expansion phase (part 2). Eligible pts in cohort 1 must have R/R cHL after autologous stem cell transplantation (ASCT) or be ineligible for ASCT and have had no prior anti-PD-1 therapy. In part 1, patients from all cohorts received pembro IV 200 mg Q3W and favezelimab IV 200 mg or 800 mg Q3W. Dose escalation followed the mTPI design. In part 2, pts received pembro + favezelimab at the established RP2D for up to 35 cycles. Primary end point was safety. Secondary end point was ORR. DOR, PFS, and OS were exploratory end points. Result(s): Only 1 dose-limiting toxicity (DLT; autoimmune hepatitis [grade 4]) was identified among the first 6 pts from all cohorts in part 1 at the favezelimab 200 mg dose; thus, the dose was escalated to 800 mg. No DLTs were observed in the 15 additional pts treated at the 800 mg dose. The RP2D for the combination was defined as 800 mg Q3W + pembro 200 mg Q3W. In cohort 1, 30 pts were enrolled; median age was 40 years, 53% had ECOG PS 0, and 80% had <=3 prior lines of therapy. After a median follow-up of 13.5 mo, ORR for cohort 1 was 73% (95% CI, 54-88; CR, 7 pts [23%]; PR, 15 pts [50%]). 28 of 30 pts (93%) had reduction from baseline in target lesions. Median DOR was not reached (NR; 95% CI, 0+ to 23+ mo); 6 pts (51%) had response >=12 mo. Median PFS was 19 mo (95% CI, 8-NR); 12-mo

Published
2022

17. Faktoren assoziiert mit Langzeitüberleben nach Versagen einer chimären Antigen-Rezeptor (CAR) T-Zell-Therapie für rezidivierte oder refraktäre großzellige B-Zell-Lymphome : eine Rolle für die allogene Stammzelltransplantation?

Author

Derigs, P., Bethge, W., Holtick, U., von Tresckow, Bastian, Ayuk, F., Penack, O., Vucinic, V., von Bonin, M., Baldus, C., Mougiakakos, D., Wulf, G., Schnetzke, U., Stelljes, M., Thomas, S., Schroers, R., Kroeger, N., and Dreger, P.

Subjects
Medizin
Published
2022

18. An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment.

Author

Lavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., and Marinello, P.

Subjects
HODGKIN'S disease, PEMBROLIZUMAB
Abstract

B Introduction: b Dual blockade of PD-1 and lymphocyte-activation gene (LAG-3) has shown antitumor activity; however, the activity of the combination for patients (pts) with relapsed or refractory (R/R) classical Hodgkin's lymphoma (cHL) is unclear. An open-label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti-PD-1 treatment Pts in cohort 1 had no prior anti-PD-1 therapy; pts in cohort 2 had progression within 12 weeks after >=2 doses of anti-PD-1 therapy, per Cheson 2007 criteria. [Extracted from the article]

Published
2023
Full Text
View/download PDF

19. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Author

Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, and Ottmann, O G

Published
2013
Full Text
View/download PDF

20. OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS

Author

Dreger, P., primary, Martus, P., additional, Holtick, U., additional, Ayuk, F., additional, Wagner‐Drouet, E. M., additional, Wulf, G., additional, Marks, R., additional, Penack, O., additional, Koenecke, C., additional, von Bonin, M., additional, von Tresckow, B., additional, Stelljes, M., additional, Baldus, C., additional, Vucinic, V., additional, Mougiakakos, D., additional, Topp, M., additional, Wolff, D., additional, Schroers, R., additional, Schmitt, M., additional, Schmitt, T., additional, Lengerke, C., additional, Thomas, S., additional, Beelen, D. W., additional, and Bethge, W., additional

Published
2021
Full Text
View/download PDF

21. A randomized study comparing two schedules of Imatinib Intervention after allogeneic stem cell transplantation (SCT) for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL): V103

Author

Pfeifer, H., Wassmann, B., Bethge, W., Dengler, J., Bornhäuser, M., Stadler, M., Beelen, D., Günther, A., Vucinic, V., Burmeister, T., Stelljes, M., Schwerdtfeger, R., Schäfer-Eckhart, K., Bader, P., Kreyenberg, H., Schuld, P., Serve, H., Hoelzer, D., Goekbuget, N., and Ottmann, O. G.

Published
2011

27. PS1243 JAK-INHIBITION WITH RUXOLITINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A PHASE II, OPEN LABEL, MULTICENTER CLINICAL TRIAL (JERICHO)

Author

Gillessen, S., primary, Pluetschow, A., additional, Vucinic, V., additional, Ostermann, H., additional, Kobe, C., additional, Broeckelmann, P.J., additional, Fuchs, M., additional, Momotow, J., additional, Borchmann, P., additional, Engert, A., additional, and Tresckow, B. von, additional

Published
2019
Full Text
View/download PDF

28. PS1240 EVEROLIMUS WITH DHAP (DEXAMETHASONE, HIGH-DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL (HD-R3I)

Author

Tresckow, B. von, primary, Hüttmann, A., additional, Vucinic, V., additional, Mueller, H., additional, Pluetschow, A., additional, Viardot, A., additional, Topp, M., additional, Bröckelmann, P., additional, Kobe, C., additional, Böll, B., additional, Eichenauer, D., additional, Sasse, S., additional, Haverkamp, H., additional, Fuchs, M., additional, Engert, A., additional, and Borchmann, P., additional

Published
2019
Full Text
View/download PDF

31. The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON-107 study

Author

Greef, G.E. (Georgine) de, Braakman, E. (Eric), Holt, B. (Bronno) van der, Janssen, J.J.W.M. (Jeroen), Petersen, E.J. (Eefke), Vucinic, V. (Vladimir), Thuss, N. (Nicole), Grootes, M.E., Cornelissen, J.J. (Jan), Greef, G.E. (Georgine) de, Braakman, E. (Eric), Holt, B. (Bronno) van der, Janssen, J.J.W.M. (Jeroen), Petersen, E.J. (Eefke), Vucinic, V. (Vladimir), Thuss, N. (Nicole), Grootes, M.E., and Cornelissen, J.J. (Jan)

Abstract

Background: Plerixafor (PFX) mobilizes CD34+ cells into circulation by disrupting the CXCR4 binding of the hematopoietic stem cell in its bone marro

Published
2018
Full Text
View/download PDF

32. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis.

Author

Pouyiourou, M., Meyer, A., Stroux, A., Viardot, A., La Rosée, P., Maschmeyer, G., Kämpfe, D., Kahl, C., Vucinic, V., Monecke, A., Hirt, C., Weber, T., Meissner, J., Witzens-Harig, M., Böttcher, S., Schmalenberg, H., Marks, R., Prange-Krex, G., Kroschinsky, F., and Hauf, E.

Subjects
RETROSPECTIVE studies, PROGRESSION-free survival, STATISTICAL significance, CLINICAL trials, FOLLICULAR lymphoma
Abstract

Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A, and 3B. Grade FL3A frequently coexists with FL1-2 (FL1-2-3A). Based on clinical trials, FL1-2 is treated with rituximab (R) or obinutuzumab plus bendamustine (B) or CHOP, while FL3B is treated with R-CHOP. In contrast, there are little data guiding therapy in FL3A. We present a retrospective, multicenter analysis of 95 FL3A or FL1-2-3A and 203 FL1-2 patients treated with R-CHOP or R-B first-line. R-CHOP facilitated a higher response rate (95% versus 76%) and longer overall survival (OS) (3-year OS 89% versus 73%, P = 0.008) in FL3A or FL1-2-3A, whereas the difference in progression-free survival (PFS) did not reach statistical significance. While transformation rates into aggressive lymphoma were similar between both groups, there were more additional malignancies after R-B compared with R-CHOP (6 versus 2 cases). In FL1-2, R-B achieved a higher 3-year PFS (79% versus 47%, P < 0.01), while there was no significant difference regarding OS or transformation. With the limitations of a retrospective analysis, these results suggest a benefit for R-CHOP over R-B in FL3A or FL1-2-3A. Confirmatory data from prospective clinical trials are needed. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

33. STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BENDAMUSTINE, PREDNISONE AND BORTEZOMIB INDUCTION IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT.

Author

Fricke, S., Wang, S., Holzhey, T., Holzvogt, M., Andrea, M., Vucinic, V., Franke, G., Heyn, S., Hell, S., Schetschorke, B., Jentzsch, M., Schwind, S., Zehrfeld, T., Braunert, L., Edelmann, T., Becker, C., Hoffmann, F., Reifenrath, K., Schwarz, M., and Schwarzer, A.

Subjects
STEM cell transplantation, MULTIPLE myeloma, STEM cells, BORTEZOMIB, PREDNISONE
Abstract

B Background: b High-dose therapy followed by autologous stem cell transplantation (ASCT) is the standard first line treatment for younger patients (<70 years) with multiple myeloma (MM). B Conclusions: b Our results indicate that the BPV induction followed by high-dose therapy and ASCT is feasible, effective and well tolerated in patients with MM-induced renal failure. B Methods: b Between October 2008 and November 2019, 135 patients with newly diagnosed MM were treated with a BPV-induction therapy consisting of bendamustine 60 mg/m SP 2 sp on days 1 and 2, bortezomib 1.3 mg/m SP 2 sp on days 1, 4, 8 and 11 and prednisone 100 mg on days 1, 2, 4, 8 and 11 followed by chemomobilization with cyclophosphamide (1-4 g/m SP 2 sp ) and ASCT. [Extracted from the article]

Published
2023
Full Text
View/download PDF

34. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Author

Bethge, WA, Martus, P, Schmitt, M, Holtick, U, Subklewe, M, von Tresckow, B, Ayuk, F, Wagner-Drouet, EM, Wulf, G, Marks, R, Penack, O, Schnetzke, U, Koenecke, C, von Bonin, M, Stelljes, M, Glass, B, Baldus, CD, Vucinic, V, Mougiakakos, D, Topp, M, Fante, M, Schroers, R, Bayir, L, Borchmann, P, Buecklein, V, Hasenkamp, J, Hanoun, C, Thomas, S, Beelen, D, Lengerke, C, Kroeger, N, and Dreger, P

Abstract

CD19-directed chimeric antigen receptor (CAR) T cells have evolved as new standard-of-care (SOC) treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR-T cell therapies with the aim to explore risk factors associated with outcome.

Published
2024
Full Text
View/download PDF

35. Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations

Author

Niederwieser, C., primary, Starke, S., additional, Fischer, L., additional, Krahl, R., additional, Beck, J., additional, Gruhn, B., additional, Ebell, W., additional, Körholz, D., additional, Wößmann, W., additional, Bader, P., additional, Lang, P., additional, Al-Ali, H-K., additional, Cross, M., additional, Eisfeld, A-K., additional, Heyn, S., additional, Vucinic, V., additional, Franke, G-N., additional, Lange, T., additional, Pönisch, W., additional, Behre, G., additional, and Christiansen, H., additional

Published
2015
Full Text
View/download PDF

36. Endpoints for clinical trials of sarcoidosis

Author

Rp, Baughman, Drent M, Da, Culver, Jc, Grutters, Handa T, Marc Humbert, Ma, Judson, Ee, Lower, Mana J, Ca, Pereira, Prasse A, Sulica R, Valyere D, Vucinic V, and Au, Wells

Subjects
Clinical Trials as Topic, Sarcoidosis, Pulmonary, Quality of Life, Disease Management, Humans, Severity of Illness Index, Respiratory Function Tests
Abstract

Over the past few years an increasing number of prospective controlled sarcoidosis treatment trials have been completed. Unfortunately, these studies utilize different endpoints making comparisons between studies difficult. At the recent World Association of Sarcoidosis and other Granulomatous disease (WASOG) meeting, a session was dedicated to the evaluation of clinical endpoints for various disease manifestations. These included pulmonary, pulmonary hypertension, fatigue, cutaneous, and a classification of clinical disease phenotypes. Based on the available literature and our current understanding of the disease, recommendations for clinical evaluation were proposed for each disease category. For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life.

Published
2013

37. A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1

Author

Hofmann, S, Fischer, A, Till, A, Müller-Quernheim, J, Häsler, R, Franke, A, Gäde, K. I, Schaarschmidt, H, Rosenstiel, P, Nebel, A, Schürmann, M, Nothnagel, M, Schreiber, S, Günther, A, Dubaniewicz, A, Pabst, S, Bumbacea, D, Prasse, A, Grubanovic, A, Rottoli, P, Bargagli, E, Bresser, P, Poletti, V, Luisetti, M, Vucinic, V, and Videnovic-Ivanov, J

Subjects
Pulmonary and Respiratory Medicine, Genetics, Linkage disequilibrium, Sarcoidosis, Chromosome Mapping, Locus (genetics), Single-nucleotide polymorphism, Genome-wide association study, Disease, Biology, Polymorphism, Single Nucleotide, Hedgehog signaling pathway, Linkage Disequilibrium, rab GTP-Binding Proteins, Gene chip analysis, Humans, Chromosomes, Human, Pair 6, Genetic Predisposition to Disease, Gene, Genome-Wide Association Study
Abstract

Sarcoidosis is a complex systemic inflammatory disease of unknown aetiology that is influenced by a variety of genetic and environmental factors. To identify further susceptibility loci for sarcoidosis, a genome-wide association study (GWAS) was conducted in 381 patients and 392 control individuals based on Affymetrix 100k GeneChip data. The top 25 single-nucleotide polymorphisms (SNPs) were selected for validation in an independent study panel (1,582 patients versus 1,783 controls). Variant rs10484410 on chromosome 6p12.1 was significantly associated, with a Bonferroni-corrected p-value of 2.90 × 10⁻² in the validation sample and a nominal p-value of 2.64 × 10⁻⁴ in the GWAS. Extensive fine mapping of the novel locus narrowed down the signal to a region comprising the genes BAG2, C6orf65, KIAA1586, ZNF451 and RAB23. Verification of the sarcoidosis-associated nonsynonymous SNP rs1040461 in a further independent case-control sample and quantitative mRNA expression studies point to the RAB23 gene as the most likely risk factor. RAB23 is proposed to be involved in antibacterial defence processes and regulation of the sonic hedgehog signalling pathway. The identified association of the 6p12.1 locus with sarcoidosis implicates this locus as a further susceptibility factor and RAB23 as a potential signalling component that may open up new perspectives in the pathophysiology of sarcoidosis.

Published
2011

38. Stem Cell Mobilization and Autologous Stem Cell Transplantation after Pretreatment consisting of Bendamustine, Prednisone and Bortezomib (BPV) in 35 Patients with newly diagnosed/untreated Multiple Myeloma

Author

Poenisch, W., primary, Plötze, M., additional, Holzvogt, B., additional, Andrea, M., additional, Schliwa, T., additional, Zehrfeld, T., additional, Hammerschmidt, D., additional, Schwarz, M., additional, Edelmann, T., additional, Becker, C., additional, Hoffmann, F.A., additional, Schwarzer, A., additional, Kreibich, U., additional, Gutsche, K., additional, Reifenrath, K., additional, Elsel, W., additional, Schwarzbach, H., additional, Bourgeois, M., additional, Heyn, S., additional, Franke, G.-N., additional, Jentzsch, M., additional, Leiblein, S., additional, Krahl, R., additional, Schwind, S., additional, Vucinic, V., additional, AlAli, H.-K., additional, and Niederwieser, D., additional

Published
2015
Full Text
View/download PDF

39. Successful Treatment of Patients With Newly Diagnosed/Untreated Light Chain Multiple Myeloma With a Combination of Bendamustine; Prednisone and Bortezomib (BPV)

Author

Mrachacz, H., primary, Khoder, N., additional, Plötze, M., additional, Holzvogt, B., additional, Andrea, M., additional, Schliwa, T., additional, Heyn, S., additional, Pfrepper, C., additional, Franke, G.N., additional, Krahl, R., additional, Jentzsch, M., additional, Leiblein, S., additional, Schwind, S., additional, Vucinic, V., additional, Niederwieser, D., additional, and Poenisch, W., additional

Published
2015
Full Text
View/download PDF

40. Effect of obesity on patient-reported outcomes in sarcoidosis

Author

Gvozdenovic, B. S., primary, Mihailovic-Vucinic, V., additional, Vukovic, M., additional, Lower, E. E., additional, Baughman, R. P., additional, Dudvarski-Ilic, A., additional, Zugic, V., additional, Popevic, S., additional, Videnovic-Ivanov, J., additional, Filipovic, S., additional, Stjepanovic, M., additional, and Omcikus, M., additional

Published
2013
Full Text
View/download PDF

41. A Randomized Phase III Trial Investigating 2 Gy TBI Vs. Flu/2 Gy TBI Conditioning for HLA-Matched Related Donor Hematopoietic Cell Transplantation (HCT): Tempo of CD3 and NK Cell Engraftment Determines Relapse and Progression Free Survival in Patients with Hematologic

Author

Kornblit, B., primary, Storer, B., additional, Storb, R.F., additional, Hari, P., additional, Vucinic, V., additional, Maziarz, R.T., additional, Chauncey, T., additional, Pulsipher, M.A., additional, Bruno, B., additional, Petersen, F.B., additional, Bethge, W.A., additional, Hubel, K., additional, Storek, J., additional, Maloney, D.G., additional, and Sandmaier, B.M., additional

Published
2012
Full Text
View/download PDF

42. Intergroup study in elderly patients with AML to compare complete remission rate and overall survival after intermediate-dose or low-dose AraC.

Author

Lange, T., primary, Niederwieser, D., additional, Hoffmann, V., additional, Pfirrmann, M., additional, Maschmeyer, G., additional, Fischer, T., additional, Herold, M., additional, Sayer, H. G., additional, Junghanss, C., additional, Krahl, R., additional, Al-Ali, H. K., additional, Pönisch, W., additional, Vucinic, V., additional, Doelken, G., additional, Sauerland, M. C., additional, Heinecke, A., additional, Hoelzer, D., additional, Hehlmann, R., additional, Berdel, W. E., additional, and Buchner, T., additional

Published
2011
Full Text
View/download PDF

45. Peracute onset of severe tumor lysis syndrome immediately after 4?Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden.

Author

Linck, D, Basara, N, Tran, V, Vucinic, V, Hermann, S, Hoelzer, D, and Fauser, A A

Subjects
HEMATOPOIETIC stem cell transplantation, TUMORS, URIC acid, COMPLICATIONS from organ transplantation
Abstract

We report a 30-year-old patient with therapy-refractory T-ALL undergoing unrelated allogeneic PBSCT. He developed severe tumor lysis syndrome (TLS) with extreme biochemical changes, cardiac and neurological symptoms and dialysis-dependent acute renal failure after TBI (4?Gy) on the first day of reduced intensity conditioning (RIC) for unrelated allogeneic PBSCT. The patient's clinical condition was stabilized after beginning daily hemodialysis and treatment for disturbed electrolytes, metabolic acidosis and plasma coagulation, as well as reduction of uric acid by rasburicase. The conditioning therapy and the allogenic PBSCT were scheduled according to the preparative regimen. According to our knowledge, severe TLS induced by 4?Gy TBI has not been reported so far. Regimen-related toxicity using RIC regimen was mild, allowing 30-50% of the patients to have an entirely outpatient transplantation. However, we would like to point out that severe TLS could also complicate PBSCT using RIC regimens in patients with relatively radiation-sensitive malignancies and high tumor burden.Bone Marrow Transplantation (2003) 31, 935-937. doi:10.1038/sj.bmt.1704025 [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

47. Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.

Author

Angelillo P, Alarcon Tomas A, Campodonico E, Novak U, Gabellier L, Blau IW, Kwon M, Ram R, Forcade E, Besley C, Vucinic V, Kröger N, Corral LL, Vydra J, Ferrari S, von Tresckow B, Rubio MT, Hernani R, Sica S, Stölzel F, Rovira M, Wagner-Drouet E, Pérez-Simón JA, Castilla-Llorente C, Ferreri AJM, Hoogenboom JD, Sanchez Ortega I, Malard F, Kuball J, and Ruggeri A

Published
2024
Full Text
View/download PDF

48. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma.

Author

Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P, Wiemers T, Weidner H, Kreuz M, Schassberger T, Kossmann J, Mangold M, Furst D, Fischer L, Baber R, Heyn S, Wang SY, Bach E, Hoffmann S, Metzeler KH, Herlling M, Jentzsch M, Franke GN, Kohl U, Friedrich M, Boldt A, Reiche K, Platzbecker U, Vucinic V, and Merz M

Abstract

Establishing a strategy for sequencing of T cell redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunological impact of bispecific T cell engaging antibodies (BsAb) as bridging therapy (BT) to subsequent BCMA-directed CAR-T cell therapies in 52 RRMM patients. BsAbs were a potent and safe option for BT, achieving the highest overall response rate (100%) to BT compared to chemotherapy, anti-CD38 or anti-SLAMF7 antibody based regimens (46%). We observed early CD4+CAR+ and delayed CD8+CAR+ T cell expansion in patients receiving BsAb as BT. In vitro cytotoxicity of CAR-T cells was comparable amongst BT options. Single-cell analyses revealed increased clonality in the CD4+ and CD8+ T cell compartments in patients with previous exposure to BsAbs at leukapheresis and on day 30 after CAR-T infusion. This study demonstrates the feasibility and efficacy of BT with BsAbs for CAR-T cell therapy in RRMM.

Published
2024
Full Text
View/download PDF

49. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.

Author

Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, Boldt A, Fricke S, Franz P, Scolnick J, Venkatraman L, Xu S, Kloetzer C, Heyn S, Kubasch AS, Baber R, Wang SY, Bach E, Hoffmann S, Ussmann J, Schetschorke B, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Köhl U, Platzbecker U, Reiche K, Vucinic V, and Merz M

Subjects
Humans, Tumor Microenvironment immunology, Single-Cell Analysis methods, Male, CD8-Positive T-Lymphocytes immunology, Neoplasm Recurrence, Local immunology, Female, Drug Resistance, Neoplasm immunology, Middle Aged, Killer Cells, Natural immunology, Aged, Multiple Myeloma immunology, Multiple Myeloma therapy, Receptors, Chimeric Antigen immunology, B-Cell Maturation Antigen immunology, Immunotherapy, Adoptive methods
Abstract

Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis. Nonresponders showed an immunosuppressive microenvironment characterized by increased numbers of monocytes expressing the immune checkpoint molecule CD39 and suppressed CD8 + T cell and natural killer cell function. Analysis of CAR T cells showed cytotoxic and exhausted phenotypes in hyperexpanded clones compared to low/intermediate expanded clones. We identified potential immunotherapy targets on CAR T cells, like PD1, to improve their functionality and durability. Our work provides evidence that an immunosuppressive microenvironment causes resistance to CAR T cell therapies in multiple myeloma., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)

Published
2024
Full Text
View/download PDF

50. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.

Author

Niedoszytko M, Gorska A, Brockow K, Bonadonna P, Lange M, Kluin-Nelemans H, Oude-Elberink H, Sabato V, Shoumariyeh K, von Bubnoff D, Müller S, Illerhaus A, Doubek M, Angelova-Fischer I, Hermine O, Arock M, Elena C, Malcovati L, Yavuz AS, Schug TD, Fortina AB, Judit V, Gotlib J, Panse J, Vucinic V, Reiter A, Schwaab J, Triggiani M, Mattsson M, Breynaert C, Romantowski J, Zanotti R, Olivieri E, Zink A, van de Ven A, Stefan A, Barete S, Caroppo F, Perkins C, Kennedy V, Christen D, Jawhar M, Luebke J, Parente R, Levedahl K, Hadzijusufovic E, Hartmann K, Nedoszytko B, Sperr WR, and Valent P

Subjects
Humans, Adult, Middle Aged, Male, Female, Aged, Prevalence, Young Adult, Adolescent, Aged, 80 and over, Pilot Projects, Risk Factors, Hypersensitivity epidemiology, Hypersensitivity diagnosis, Registries, Mastocytosis epidemiology, Mastocytosis diagnosis, Mastocytosis complications
Abstract

Background: Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies in a larger cohort of mastocytosis patients. We assessed prevalence, triggers and risk factors of HR in adults with mastocytosis in the ECNM registry., Methods: Data were collected in 27 ECNM centers. We analyzed potential triggers (Hymenoptera venoms, food, drug, inhalant and others) and risk factors at diagnosis and during follow-up. The study group consisted of 2485 adults with mastocytosis, 1379 women (55.5%) and 1106 men (44.5%). Median age was 48.2 years (range 18-91 years)., Results: Nine hundred and forty eight patients (38.1%) reported one or more HR`. Most common triggers were Hymenoptera venoms in cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), whereas in advanced SM (advSM), most common elicitors were drugs, including nonsteroidal anti-inflammatory agents and penicillin. In multivariate analyses, tryptase level < 90 ng/mL, <15% infiltration by mast cells in bone marrow biopsy-sections, and diagnosis of ISM were identified as independent risk factors for HR. For drug-induced HR, prominent risk factors were advSM and high tryptase levels. New reactions were observed in 4.8% of all patients during 4 years follow-up., Conclusions: HR are mainly triggered by Hymenoptera venoms in patients with CM and ISM and by drugs in patients with advSM. Tryptase levels <90 ng/mL, mast cell bone marrow infiltration <15%, and WHO category ISM are predictors of HR. New HR occur in 4.8% of all patients within 4 years., (© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results